目的:研究^(125)I粒子植入对免疫微环境的影响,以及^(125)I粒子植入联合抗程序性死亡受体-1(programmed cell death receptor-1,PD-1)治疗的抗肿瘤疗效。方法:在小鼠右后肢皮下注射Lewis肺癌(LLC)细胞构建肿瘤模型,利用流式细胞术分析^(...目的:研究^(125)I粒子植入对免疫微环境的影响,以及^(125)I粒子植入联合抗程序性死亡受体-1(programmed cell death receptor-1,PD-1)治疗的抗肿瘤疗效。方法:在小鼠右后肢皮下注射Lewis肺癌(LLC)细胞构建肿瘤模型,利用流式细胞术分析^(125)I粒子植入后PD-1、程序性死亡配体1(programmed death-ligand 1,PD-L1)、Treg细胞的表达。在小鼠右后肢(原位肿瘤)和左前肢(远位肿瘤)皮下注射LLC细胞,将小鼠随机分为PBS组、抗PD-1组、^(125)I粒子植入组和联合治疗组。绘制肿瘤生长曲线,流式分析肿瘤浸润CD4^(+)及CD8^(+)T细胞比例。结果:^(125)I粒子植入12天后PD-L1及PD-1表达上调(P<0.01),Treg表达无显著性差异(P=0.196)。与其余各组相比,联合治疗组小鼠原位和远位肿瘤生长均受到明显抑制(均P<0.05),肿瘤浸润CD8^(+)T细胞比例显著增加(均P<0.05)。结论:^(125)I粒子植入联合抗PD-1治疗能激活机体抗肿瘤免疫,协同抑制小鼠LLC生长。展开更多
AIM:To study the associations between lysyl oxidaselike 1(LOXL1)polymorphisms and primary open angle glaucoma(POAG)remain inconsistent.In this study,we have performed a meta-analysis to investigate the association of ...AIM:To study the associations between lysyl oxidaselike 1(LOXL1)polymorphisms and primary open angle glaucoma(POAG)remain inconsistent.In this study,we have performed a meta-analysis to investigate the association of LOXL1 polymorphisms with POAG risk.METHODS:Published literature from PubMed and other databases were retrieved.All studies evaluating the association between LOXL1 polymorphisms(rs2165241,rs1048661,rs3825942)and POAG risk were included.Pooled odds ratio(OR)and 95%confidence interval(CI)were calculated using random-or fixed-effects model.RESULTS:Twelve studies were identified as eligible articles,with thirteen(2098 cases and 16 473 controls),thirteen(1795 cases and 2916 controls)and sixteen population cohorts(2456 cases and 2846 controls)for the association of rs2165241,rs1048661 and rs3825942with POAG risk respectively.Overall analyses showed noassociation between each LOXL1 polymorphism and POAG risk,and the negative associations were remained when the subjects were stratified as Caucasian and Asian.The heterozygote of rs2165241 was associated with reduced POAG risk in hospital-based populations(TC vs CC:OR,0.79,95%CI:0.63-0.99),and rs1048661was associated with increased POAG risk in hospitalbased populations in a dominant model(TT vs CC+CT:OR,1.23,95%CI:1.01-1.50);however,these associations were not found in population-based subjects.CONCLUSION:This meta-analysis suggests that LOXL1 polymorphisms are not associated with POAG risk.Given the limited sample size,the associations of LOXL1 polymorphisms with POAG risk in hospital-based populations await further investigation.展开更多
基金Supported by the Zhejiang Provincial Educational Bureau Foundation,China(Y201223905)
文摘AIM:To study the associations between lysyl oxidaselike 1(LOXL1)polymorphisms and primary open angle glaucoma(POAG)remain inconsistent.In this study,we have performed a meta-analysis to investigate the association of LOXL1 polymorphisms with POAG risk.METHODS:Published literature from PubMed and other databases were retrieved.All studies evaluating the association between LOXL1 polymorphisms(rs2165241,rs1048661,rs3825942)and POAG risk were included.Pooled odds ratio(OR)and 95%confidence interval(CI)were calculated using random-or fixed-effects model.RESULTS:Twelve studies were identified as eligible articles,with thirteen(2098 cases and 16 473 controls),thirteen(1795 cases and 2916 controls)and sixteen population cohorts(2456 cases and 2846 controls)for the association of rs2165241,rs1048661 and rs3825942with POAG risk respectively.Overall analyses showed noassociation between each LOXL1 polymorphism and POAG risk,and the negative associations were remained when the subjects were stratified as Caucasian and Asian.The heterozygote of rs2165241 was associated with reduced POAG risk in hospital-based populations(TC vs CC:OR,0.79,95%CI:0.63-0.99),and rs1048661was associated with increased POAG risk in hospitalbased populations in a dominant model(TT vs CC+CT:OR,1.23,95%CI:1.01-1.50);however,these associations were not found in population-based subjects.CONCLUSION:This meta-analysis suggests that LOXL1 polymorphisms are not associated with POAG risk.Given the limited sample size,the associations of LOXL1 polymorphisms with POAG risk in hospital-based populations await further investigation.
基金the National Natural Science Foundation of China (Grant No.51376123)Shanghai Sailing Program (Grant No.17YF1409800)China's Post-Doctoral Science Fund (No.2017M611561).
